

Results from the first JPIAMR transnational call InnovaResistance: Innovative approaches to address antibacterial resistance

The largest global initiative on Antimicrobial Resistance has nominated 7 consortia out of 40 for funding with partners from 11 different countries with a total suggested funding of more than 8 million Euros. The nominated projects cover areas within prevention of infection, treatment (therapy) development, drug development, target identification for antibacterial drug development, and pharmacokinetics.

- The evaluated applications illustrated the depth and breadth of the research associated with AMR in Europe and Canada. They covered diverse aspects related to acquisition, spread and mechanisms of AMR as well as development of novel antibiotics, bactericidal peptides, anti-virulence compounds and bacteriophage therapy. I am confident that the recommended proposals will make significant contributions to the fight against bacterial infections in the future, says Gad M Frankel, chair of the peer review panel.

InnovaResistance, published in January 2014, is the first joint transnational call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) consisting of 19 nations. The call was promoted by 14 funding agencies from 12 countries with a total budget of 13,8M€.

- I am very pleased that we now have the first nominated projects within the Joint Programming Initiative on Antimicrobial Resistance, says Mats Ulfendahl, chair of the Management Board.

The evaluation has been a two-stage process and the proposed projects have been evaluated by a peer review panel based on scientific quality. Based on the recommendation and available funding seven projects have now been nominated for funding. The final decision is now being made at national levels. Projects will start at the end of 2014 or beginning of 2015.